MXPA05005432A - Quinolinil-pirrolopirazoles. - Google Patents

Quinolinil-pirrolopirazoles.

Info

Publication number
MXPA05005432A
MXPA05005432A MXPA05005432A MXPA05005432A MXPA05005432A MX PA05005432 A MXPA05005432 A MX PA05005432A MX PA05005432 A MXPA05005432 A MX PA05005432A MX PA05005432 A MXPA05005432 A MX PA05005432A MX PA05005432 A MXPA05005432 A MX PA05005432A
Authority
MX
Mexico
Prior art keywords
pyrrolopyrazoles
quinolinyl
compound
administration
patient
Prior art date
Application number
MXPA05005432A
Other languages
English (en)
Inventor
Michael Yingling Jonathan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA05005432A publication Critical patent/MXPA05005432A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuesto segun la formula II y las sales farmaceuticamente aceptables del mismo y el procedimiento de tratamiento del cancer en un paciente en necesidad del mismo mediante la administracion del citado compuesto.
MXPA05005432A 2002-11-22 2003-11-10 Quinolinil-pirrolopirazoles. MXPA05005432A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42889302P 2002-11-22 2002-11-22
PCT/US2003/032747 WO2004048382A1 (en) 2002-11-22 2003-11-10 Quinolinyl-pyrrolopyrazoles

Publications (1)

Publication Number Publication Date
MXPA05005432A true MXPA05005432A (es) 2005-08-03

Family

ID=32393478

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005432A MXPA05005432A (es) 2002-11-22 2003-11-10 Quinolinil-pirrolopirazoles.

Country Status (29)

Country Link
US (2) US7265225B2 (es)
EP (1) EP1565471B1 (es)
JP (1) JP4542906B2 (es)
KR (1) KR101057282B1 (es)
CN (1) CN100345852C (es)
AT (1) ATE341550T1 (es)
AU (1) AU2003291643B2 (es)
BR (1) BR0315337A (es)
CA (1) CA2501322C (es)
CO (1) CO5570677A2 (es)
CR (1) CR7830A (es)
CY (1) CY1106283T1 (es)
DE (1) DE60308893T2 (es)
DK (1) DK1565471T3 (es)
EA (1) EA008387B1 (es)
EC (1) ECSP055807A (es)
EG (1) EG25822A (es)
ES (1) ES2273046T3 (es)
HK (1) HK1081948A1 (es)
HR (1) HRP20050436B1 (es)
IL (1) IL168190A (es)
MX (1) MXPA05005432A (es)
NO (1) NO331403B1 (es)
NZ (1) NZ538942A (es)
PL (1) PL227840B1 (es)
PT (1) PT1565471E (es)
UA (1) UA80571C2 (es)
WO (1) WO2004048382A1 (es)
ZA (1) ZA200503121B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405299B2 (en) * 2002-11-27 2008-07-29 Eli Lilly And Company Compounds as pharmaceutical agents
US7872020B2 (en) * 2005-07-22 2011-01-18 Eli Lilly And Company TGF-β inhibitors
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
EP2083863B1 (en) 2006-10-03 2015-03-18 Genzyme Corporation Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
EP2074128B1 (en) * 2006-10-16 2013-08-14 Medicis Pharmaceutical Corporation Therapeutic pyrazolyl thienopyridines
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
PE20141558A1 (es) 2012-04-20 2014-11-06 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
EA039595B1 (ru) 2012-10-05 2022-02-15 Кадмон Корпорейшн, Ллк Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела
EP2917365B1 (en) 2012-11-12 2020-03-11 Institució Catalana de Recerca i Estudis Avançats Methods and kits for the prognosis of colorectal cancer
TWI582083B (zh) 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
US10822337B2 (en) 2015-04-01 2020-11-03 Rigel Pharmaceuticals, Inc. TGF-β inhibitorC
KR20180094036A (ko) 2015-12-15 2018-08-22 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
CN110582497B (zh) * 2017-03-17 2022-03-11 杭州领业医药科技有限公司 Galunisertib的晶型及其制备方法和药物组合物
CN110582279B (zh) * 2017-03-21 2023-07-14 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
EP3827010A4 (en) 2018-07-23 2022-03-16 Brise Pharmaceuticals Co., Ltd. BISPHOSPHONATE-DRUG CONJUGATES
KR20210110316A (ko) 2018-12-27 2021-09-07 넥시스 테라퓨틱스 인코포레이티드 암의 치료를 위한 tgf-베타 r1(alk5) 억제제로서의(피리딘-2-일)아민 유도체
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN113557236B (zh) * 2019-06-10 2022-05-10 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
KR20220143063A (ko) 2020-02-19 2022-10-24 남미 테라퓨틱스, 인크. 암의 치료에 유용한 TGFβ 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DK1206474T3 (da) * 1999-08-27 2004-10-04 Abbott Lab Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
SI1397364T1 (sl) * 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
EP1567528A1 (en) 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators

Also Published As

Publication number Publication date
US20080027102A1 (en) 2008-01-31
CY1106283T1 (el) 2011-10-12
AU2003291643B2 (en) 2010-05-13
DE60308893T2 (de) 2007-03-15
HRP20050436A2 (en) 2005-10-31
CO5570677A2 (es) 2005-10-31
NO20053045L (no) 2005-06-21
JP2006514012A (ja) 2006-04-27
EA200500859A1 (ru) 2005-10-27
KR101057282B1 (ko) 2011-08-16
EG25822A (en) 2012-08-23
KR20050083945A (ko) 2005-08-26
CA2501322A1 (en) 2004-06-10
DK1565471T3 (da) 2007-02-05
ES2273046T3 (es) 2007-05-01
HRP20050436B1 (hr) 2013-11-08
EP1565471B1 (en) 2006-10-04
JP4542906B2 (ja) 2010-09-15
DE60308893D1 (de) 2006-11-16
US7834029B2 (en) 2010-11-16
HK1081948A1 (en) 2006-05-26
NO331403B1 (no) 2011-12-19
WO2004048382A1 (en) 2004-06-10
ZA200503121B (en) 2006-07-26
PT1565471E (pt) 2007-01-31
ECSP055807A (es) 2005-08-11
CN100345852C (zh) 2007-10-31
EP1565471A1 (en) 2005-08-24
CR7830A (es) 2005-06-20
EA008387B1 (ru) 2007-04-27
IL168190A (en) 2011-01-31
AU2003291643A1 (en) 2004-06-18
ATE341550T1 (de) 2006-10-15
CA2501322C (en) 2011-05-10
UA80571C2 (en) 2007-10-10
US20060040983A1 (en) 2006-02-23
US7265225B2 (en) 2007-09-04
BR0315337A (pt) 2005-08-16
NZ538942A (en) 2007-01-26
CN1714090A (zh) 2005-12-28
PL376797A1 (pl) 2006-01-09
PL227840B1 (pl) 2018-01-31

Similar Documents

Publication Publication Date Title
EG25822A (en) Quinolinyl-pyrrolopyrazoles
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
SG2013013339A (en) N3 alkylated benzimidazole derivatives as mek inhibitors
WO2004045523A3 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
GB0130677D0 (en) Medicaments and novel compounds
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
NO20003313D0 (no) Terapeutiske midler
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
MY133107A (en) Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
PL1648473T3 (pl) Pojedyncza dawka szybko rozpuszczającej się azytromycyny
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
MXPA05011418A (es) Metodo para administracion de troxacitabina.
CY1109852T1 (el) Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
AU2002211217A1 (en) Method of treating stroke
EP1547596A4 (en) MEDICAL COMPOSITION AND METHOD FOR THE TREATMENT OF MALIGNANT TUMORS AND THE USE THEREOF
JO2829B1 (en) Pyridazine derivatives and their use as therapeutic agents

Legal Events

Date Code Title Description
FG Grant or registration